Journal
CELL REPORTS
Volume 34, Issue 1, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2020.108585
Keywords
-
Categories
Funding
- National Health and Medical Research Council of Australia [1121057, 1083961, 1138242, 1002648, 1118170]
- Cancer Council South Australia [1185012]
- Principal Cancer Research Fellowships - Cancer Council's Beat Cancer project on behalf of its donors
- state Government through the Department of Health
- Australian Government through the Medical Research Future Fund
- NBCF Fellowship [IIRS-19-009]
- Victorian Government through the Victorian Cancer Agency [MCRF18017, MCRF15023]
- Movember Foundation
- Prostate Cancer Foundation of Australia through Movember Revolutionary Team Awards
- National Health and Medical Research Council of Australia [1138242, 1121057, 1118170, 1083961] Funding Source: NHMRC
Ask authors/readers for more resources
miR-194 acts as a regulator of epithelial-neuroendocrine transdifferentiation in prostate cancer cells, with elevated expression in NEPC and the ability to directly target genes involved in neuroendocrine features. Inhibition of miR-194 can block transdifferentiation and inhibit the growth of NEPC cell lines and patient-derived organoids.
Potent therapeutic inhibition of the androgen receptor (AR) in prostate adenocarcinoma can lead to the emergence of neuroendocrine prostate cancer (NEPC), a phenomenon associated with enhanced cell plasticity. Here, we show that microRNA-194 (miR-194) is a regulator of epithelial-neuroendocrine transdifferentiation. In clinical prostate cancer samples, miR-194 expression and activity were elevated in NEPC and inversely correlated with AR signaling. miR-194 facilitated the emergence of neuroendocrine features in prostate cancer cells, a process mediated by its ability to directly target a suite of genes involved in cell plasticity. One such target was FOXA1, which encodes a transcription factor with a vital role in maintaining the prostate epithelial lineage. Importantly, a miR-194 inhibitor blocked epithelial-neuroendocrine transdifferentiation and inhibited the growth of cell lines and patient-derived organoids possessing neuroendocrine features. Overall, our study reveals a post-transcriptional mechanism regulating the plasticity of prostate cancer cells and provides a rationale for targeting miR-194 in NEPC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available